Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl Article Swipe
Bradley D. Stein
,
Flora Sheng
,
Brendan Saloner
,
Adam J. Gordon
,
Jessica S. Merlin
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1186/s13722-025-00547-0
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1186/s13722-025-00547-0
Background In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA’s recommended target daily dose (16 mg) and maximum suggested daily dose (24 mg) may provide better outcomes, but little is known about higher dosage prescribing patterns. To better understand buprenorphine prescribing patterns, this manuscript examines the frequency and characteristics of dispensed buprenorphine of ≤ 16mg, > 16-24 mg, and > 24 mg daily dose. Methods We used IQVIA data to conduct a cross-sectional study of opioid use disorder-indicated buprenorphine prescriptions dispensed at retail pharmacies January 2019 - December 2020; categorized prescriptions as ≤ 16mg, > 16 to 24 mg, and > 24 mg daily dose; and examined overall rates and rates by patient, insurer and county characteristics, and prescriber specialty. We categorized buprenorphine prescriptions by patient sex, age cohort, primary payment source, and prescriber specialty and state and conducted univariate and bivariate analyses of buprenorphine daily dose categories overall and among clinicians frequently prescribing buprenorphine at the highest doses, > 24 mg. Results Approximately 19.5% ( n = 5,568,964) of the 28 million buprenorphine prescriptions from 68,898 clinicians were > 16-24 mg; 2% ( n = 641,390) were > 24 mg. Approximately 26% ( n = 17,939) of clinicians wrote at least one prescription > 24 mg; 2,780 clinicians (4% of buprenorphine prescribers) were responsible for 82.2% ( n = 527,597) of dispensed prescriptions > 24 mg. 28% of prescriptions > 24 mg written by these prescribers were cash-pay, 12.5% covered by Medicaid, and 6.7% covered by Medicare. There was no correlation between state fentanyl overdose rate and buprenorphine prescriptions > 24 mg per 1,000,000 residents. Conclusions In 2019–2020, fewer than 3% of dispensed buprenorphine prescriptions exceeded the FDA suggested maximum of 24 mg daily dose; 80% of the prescriptions for a > 24 mg daily dose were written by 4% of buprenorphine prescribers. As clinicians and policymakers pay greater attention to ensuring individuals are receiving buprenorphine dosages adequate to effectively treat their opioid use disorder, the recently revised FDA recommendations may encourage such behavior. Additionally, disproportionate reliance on cash payment for higher daily doses suggests public and private insurers could facilitate access to such treatment when appropriate.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1186/s13722-025-00547-0
- https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0
- OA Status
- gold
- Cited By
- 1
- References
- 32
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4409308874
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4409308874Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1186/s13722-025-00547-0Digital Object Identifier
- Title
-
Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanylWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-04-09Full publication date if available
- Authors
-
Bradley D. Stein, Flora Sheng, Brendan Saloner, Adam J. Gordon, Jessica S. MerlinList of authors in order
- Landing page
-
https://doi.org/10.1186/s13722-025-00547-0Publisher landing page
- PDF URL
-
https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0Direct OA link when available
- Concepts
-
Buprenorphine, Medicine, Medical prescription, Specialty, Defined daily dose, Emergency medicine, Methadone, Cross-sectional study, Fentanyl, Family medicine, Opioid, Anesthesia, Internal medicine, Pharmacology, Receptor, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
32Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4409308874 |
|---|---|
| doi | https://doi.org/10.1186/s13722-025-00547-0 |
| ids.doi | https://doi.org/10.1186/s13722-025-00547-0 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40205451 |
| ids.openalex | https://openalex.org/W4409308874 |
| fwci | 6.47427621 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000008 |
| mesh[1].descriptor_ui | D002047 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | administration & dosage |
| mesh[1].descriptor_name | Buprenorphine |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D002047 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Buprenorphine |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D003430 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Cross-Sectional Studies |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005283 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Fentanyl |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D008297 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Male |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D005260 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Female |
| mesh[7].qualifier_ui | Q000706 |
| mesh[7].descriptor_ui | D010818 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | statistics & numerical data |
| mesh[7].descriptor_name | Practice Patterns, Physicians' |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D009293 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Opioid-Related Disorders |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D000328 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Adult |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D008875 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Middle Aged |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D014481 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | United States |
| mesh[12].qualifier_ui | Q000008 |
| mesh[12].descriptor_ui | D000701 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | administration & dosage |
| mesh[12].descriptor_name | Analgesics, Opioid |
| mesh[13].qualifier_ui | Q000008 |
| mesh[13].descriptor_ui | D009292 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | administration & dosage |
| mesh[13].descriptor_name | Narcotic Antagonists |
| mesh[14].qualifier_ui | Q000706 |
| mesh[14].descriptor_ui | D011307 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | statistics & numerical data |
| mesh[14].descriptor_name | Drug Prescriptions |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D055815 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Young Adult |
| mesh[16].qualifier_ui | Q000379 |
| mesh[16].descriptor_ui | D058850 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | methods |
| mesh[16].descriptor_name | Opiate Substitution Treatment |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000293 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Adolescent |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D004305 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Dose-Response Relationship, Drug |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D006801 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Humans |
| mesh[20].qualifier_ui | Q000008 |
| mesh[20].descriptor_ui | D002047 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | administration & dosage |
| mesh[20].descriptor_name | Buprenorphine |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D002047 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Buprenorphine |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D003430 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Cross-Sectional Studies |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D005283 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Fentanyl |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D008297 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Male |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D005260 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Female |
| mesh[26].qualifier_ui | Q000706 |
| mesh[26].descriptor_ui | D010818 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | statistics & numerical data |
| mesh[26].descriptor_name | Practice Patterns, Physicians' |
| mesh[27].qualifier_ui | Q000188 |
| mesh[27].descriptor_ui | D009293 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | drug therapy |
| mesh[27].descriptor_name | Opioid-Related Disorders |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000328 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Adult |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D008875 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Middle Aged |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D014481 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | United States |
| mesh[31].qualifier_ui | Q000008 |
| mesh[31].descriptor_ui | D000701 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | administration & dosage |
| mesh[31].descriptor_name | Analgesics, Opioid |
| mesh[32].qualifier_ui | Q000008 |
| mesh[32].descriptor_ui | D009292 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | administration & dosage |
| mesh[32].descriptor_name | Narcotic Antagonists |
| mesh[33].qualifier_ui | Q000706 |
| mesh[33].descriptor_ui | D011307 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | statistics & numerical data |
| mesh[33].descriptor_name | Drug Prescriptions |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D055815 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Young Adult |
| mesh[35].qualifier_ui | Q000379 |
| mesh[35].descriptor_ui | D058850 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | methods |
| mesh[35].descriptor_name | Opiate Substitution Treatment |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D000293 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Adolescent |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D004305 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Dose-Response Relationship, Drug |
| type | article |
| title | Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl |
| awards[0].id | https://openalex.org/G1166221993 |
| awards[0].funder_id | https://openalex.org/F4320337347 |
| awards[0].display_name | |
| awards[0].funder_award_id | R01DA045800 |
| awards[0].funder_display_name | National Institute on Drug Abuse |
| biblio.issue | 1 |
| biblio.volume | 20 |
| biblio.last_page | 33 |
| biblio.first_page | 33 |
| grants[0].funder | https://openalex.org/F4320337347 |
| grants[0].award_id | R01DA045800 |
| grants[0].funder_display_name | National Institute on Drug Abuse |
| topics[0].id | https://openalex.org/T10576 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2739 |
| topics[0].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[0].display_name | Opioid Use Disorder Treatment |
| topics[1].id | https://openalex.org/T11199 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9951000213623047 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2703 |
| topics[1].subfield.display_name | Anesthesiology and Pain Medicine |
| topics[1].display_name | Pain Management and Opioid Use |
| topics[2].id | https://openalex.org/T11635 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.994700014591217 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2711 |
| topics[2].subfield.display_name | Emergency Medicine |
| topics[2].display_name | Poisoning and overdose treatments |
| funders[0].id | https://openalex.org/F4320337347 |
| funders[0].ror | https://ror.org/00fq5cm18 |
| funders[0].display_name | National Institute on Drug Abuse |
| is_xpac | False |
| apc_list.value | 1790 |
| apc_list.currency | GBP |
| apc_list.value_usd | 2195 |
| apc_paid.value | 1790 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 2195 |
| concepts[0].id | https://openalex.org/C2778949969 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9380722045898438 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q407721 |
| concepts[0].display_name | Buprenorphine |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8507695198059082 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2426938 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7614222764968872 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3355478 |
| concepts[2].display_name | Medical prescription |
| concepts[3].id | https://openalex.org/C20387591 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5200071930885315 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q930752 |
| concepts[3].display_name | Specialty |
| concepts[4].id | https://openalex.org/C2776865356 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5154972672462463 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1182681 |
| concepts[4].display_name | Defined daily dose |
| concepts[5].id | https://openalex.org/C194828623 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4707629978656769 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2861470 |
| concepts[5].display_name | Emergency medicine |
| concepts[6].id | https://openalex.org/C2778767360 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4682188034057617 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q179996 |
| concepts[6].display_name | Methadone |
| concepts[7].id | https://openalex.org/C142052008 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4276221990585327 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q954027 |
| concepts[7].display_name | Cross-sectional study |
| concepts[8].id | https://openalex.org/C2781072394 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4174475073814392 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q407541 |
| concepts[8].display_name | Fentanyl |
| concepts[9].id | https://openalex.org/C512399662 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3464232087135315 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q3505712 |
| concepts[9].display_name | Family medicine |
| concepts[10].id | https://openalex.org/C2781063702 |
| concepts[10].level | 3 |
| concepts[10].score | 0.28130286931991577 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q427523 |
| concepts[10].display_name | Opioid |
| concepts[11].id | https://openalex.org/C42219234 |
| concepts[11].level | 1 |
| concepts[11].score | 0.26826244592666626 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q131130 |
| concepts[11].display_name | Anesthesia |
| concepts[12].id | https://openalex.org/C126322002 |
| concepts[12].level | 1 |
| concepts[12].score | 0.19947665929794312 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[12].display_name | Internal medicine |
| concepts[13].id | https://openalex.org/C98274493 |
| concepts[13].level | 1 |
| concepts[13].score | 0.15863457322120667 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[13].display_name | Pharmacology |
| concepts[14].id | https://openalex.org/C170493617 |
| concepts[14].level | 2 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[14].display_name | Receptor |
| concepts[15].id | https://openalex.org/C142724271 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[15].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/buprenorphine |
| keywords[0].score | 0.9380722045898438 |
| keywords[0].display_name | Buprenorphine |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8507695198059082 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/medical-prescription |
| keywords[2].score | 0.7614222764968872 |
| keywords[2].display_name | Medical prescription |
| keywords[3].id | https://openalex.org/keywords/specialty |
| keywords[3].score | 0.5200071930885315 |
| keywords[3].display_name | Specialty |
| keywords[4].id | https://openalex.org/keywords/defined-daily-dose |
| keywords[4].score | 0.5154972672462463 |
| keywords[4].display_name | Defined daily dose |
| keywords[5].id | https://openalex.org/keywords/emergency-medicine |
| keywords[5].score | 0.4707629978656769 |
| keywords[5].display_name | Emergency medicine |
| keywords[6].id | https://openalex.org/keywords/methadone |
| keywords[6].score | 0.4682188034057617 |
| keywords[6].display_name | Methadone |
| keywords[7].id | https://openalex.org/keywords/cross-sectional-study |
| keywords[7].score | 0.4276221990585327 |
| keywords[7].display_name | Cross-sectional study |
| keywords[8].id | https://openalex.org/keywords/fentanyl |
| keywords[8].score | 0.4174475073814392 |
| keywords[8].display_name | Fentanyl |
| keywords[9].id | https://openalex.org/keywords/family-medicine |
| keywords[9].score | 0.3464232087135315 |
| keywords[9].display_name | Family medicine |
| keywords[10].id | https://openalex.org/keywords/opioid |
| keywords[10].score | 0.28130286931991577 |
| keywords[10].display_name | Opioid |
| keywords[11].id | https://openalex.org/keywords/anesthesia |
| keywords[11].score | 0.26826244592666626 |
| keywords[11].display_name | Anesthesia |
| keywords[12].id | https://openalex.org/keywords/internal-medicine |
| keywords[12].score | 0.19947665929794312 |
| keywords[12].display_name | Internal medicine |
| keywords[13].id | https://openalex.org/keywords/pharmacology |
| keywords[13].score | 0.15863457322120667 |
| keywords[13].display_name | Pharmacology |
| language | en |
| locations[0].id | doi:10.1186/s13722-025-00547-0 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S152134104 |
| locations[0].source.issn | 1940-0632, 1940-0640 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1940-0632 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Addiction Science & Clinical Practice |
| locations[0].source.host_organization | https://openalex.org/P4310320256 |
| locations[0].source.host_organization_name | BioMed Central |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| locations[0].source.host_organization_lineage_names | BioMed Central, Springer Nature |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Addiction Science & Clinical Practice |
| locations[0].landing_page_url | https://doi.org/10.1186/s13722-025-00547-0 |
| locations[1].id | pmid:40205451 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Addiction science & clinical practice |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40205451 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11980160 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Addict Sci Clin Pract |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11980160 |
| locations[3].id | pmh:oai:doaj.org/article:94341fb4e3b84fe1ba94fe006c419505 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Addiction Science & Clinical Practice, Vol 20, Iss 1, Pp 1-9 (2025) |
| locations[3].landing_page_url | https://doaj.org/article/94341fb4e3b84fe1ba94fe006c419505 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5102897631 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-8868-8887 |
| authorships[0].author.display_name | Bradley D. Stein |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1309849503 |
| authorships[0].affiliations[0].raw_affiliation_string | RAND, Pittsburgh, PA, USA. [email protected]. |
| authorships[0].institutions[0].id | https://openalex.org/I1309849503 |
| authorships[0].institutions[0].ror | https://ror.org/00f2z7n96 |
| authorships[0].institutions[0].type | nonprofit |
| authorships[0].institutions[0].lineage | https://openalex.org/I1309849503 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | RAND Corporation |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Bradley D Stein |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | RAND, Pittsburgh, PA, USA. [email protected]. |
| authorships[1].author.id | https://openalex.org/A5075764338 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-1511-6754 |
| authorships[1].author.display_name | Flora Sheng |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1309849503 |
| authorships[1].affiliations[0].raw_affiliation_string | RAND, Arlington, VA, USA. |
| authorships[1].institutions[0].id | https://openalex.org/I1309849503 |
| authorships[1].institutions[0].ror | https://ror.org/00f2z7n96 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I1309849503 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | RAND Corporation |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Flora Sheng |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | RAND, Arlington, VA, USA. |
| authorships[2].author.id | https://openalex.org/A5017119046 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9013-3023 |
| authorships[2].author.display_name | Brendan Saloner |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I145311948 |
| authorships[2].affiliations[0].raw_affiliation_string | Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. |
| authorships[2].institutions[0].id | https://openalex.org/I145311948 |
| authorships[2].institutions[0].ror | https://ror.org/00za53h95 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I145311948 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Johns Hopkins University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Brendan K Saloner |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. |
| authorships[3].author.id | https://openalex.org/A5036614428 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-2453-8871 |
| authorships[3].author.display_name | Adam J. Gordon |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210089864 |
| authorships[3].affiliations[0].raw_affiliation_string | Informatics, Decision-Enhancement, and Analytic Sciences Center, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA. |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I223532165 |
| authorships[3].affiliations[1].raw_affiliation_string | Program for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. |
| authorships[3].institutions[0].id | https://openalex.org/I223532165 |
| authorships[3].institutions[0].ror | https://ror.org/03r0ha626 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I223532165 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | University of Utah |
| authorships[3].institutions[1].id | https://openalex.org/I4210089864 |
| authorships[3].institutions[1].ror | https://ror.org/007fyq698 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I1322918889, https://openalex.org/I2799886695, https://openalex.org/I4210089864, https://openalex.org/I4210113540 |
| authorships[3].institutions[1].country_code | US |
| authorships[3].institutions[1].display_name | VA Salt Lake City Healthcare System |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Adam J Gordon |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Informatics, Decision-Enhancement, and Analytic Sciences Center, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA., Program for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. |
| authorships[4].author.id | https://openalex.org/A5053069821 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-3207-4875 |
| authorships[4].author.display_name | Jessica S. Merlin |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I170201317 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. |
| authorships[4].institutions[0].id | https://openalex.org/I170201317 |
| authorships[4].institutions[0].ror | https://ror.org/01an3r305 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I170201317 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | University of Pittsburgh |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Jessica S Merlin |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10576 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2739 |
| primary_topic.subfield.display_name | Public Health, Environmental and Occupational Health |
| primary_topic.display_name | Opioid Use Disorder Treatment |
| related_works | https://openalex.org/W2519672434, https://openalex.org/W3000877141, https://openalex.org/W2012590588, https://openalex.org/W4399730973, https://openalex.org/W1979517098, https://openalex.org/W4205298653, https://openalex.org/W1991355918, https://openalex.org/W2966942633, https://openalex.org/W2087129163, https://openalex.org/W2139110642 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1186/s13722-025-00547-0 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S152134104 |
| best_oa_location.source.issn | 1940-0632, 1940-0640 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1940-0632 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Addiction Science & Clinical Practice |
| best_oa_location.source.host_organization | https://openalex.org/P4310320256 |
| best_oa_location.source.host_organization_name | BioMed Central |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_lineage_names | BioMed Central, Springer Nature |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Addiction Science & Clinical Practice |
| best_oa_location.landing_page_url | https://doi.org/10.1186/s13722-025-00547-0 |
| primary_location.id | doi:10.1186/s13722-025-00547-0 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S152134104 |
| primary_location.source.issn | 1940-0632, 1940-0640 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1940-0632 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Addiction Science & Clinical Practice |
| primary_location.source.host_organization | https://openalex.org/P4310320256 |
| primary_location.source.host_organization_name | BioMed Central |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| primary_location.source.host_organization_lineage_names | BioMed Central, Springer Nature |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://ascpjournal.biomedcentral.com/counter/pdf/10.1186/s13722-025-00547-0 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Addiction Science & Clinical Practice |
| primary_location.landing_page_url | https://doi.org/10.1186/s13722-025-00547-0 |
| publication_date | 2025-04-09 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4385334522, https://openalex.org/W2808907017, https://openalex.org/W3021231807, https://openalex.org/W4392883104, https://openalex.org/W4386818406, https://openalex.org/W2909204744, https://openalex.org/W4289928095, https://openalex.org/W3037586716, https://openalex.org/W2912453779, https://openalex.org/W2975416421, https://openalex.org/W2990871804, https://openalex.org/W2149717129, https://openalex.org/W3090371256, https://openalex.org/W4380885486, https://openalex.org/W2073606903, https://openalex.org/W4401103232, https://openalex.org/W4402842748, https://openalex.org/W2002129794, https://openalex.org/W2040327352, https://openalex.org/W1971962043, https://openalex.org/W4367693677, https://openalex.org/W3165852740, https://openalex.org/W2476427000, https://openalex.org/W2983734219, https://openalex.org/W4394858340, https://openalex.org/W2914274185, https://openalex.org/W4391350645, https://openalex.org/W4380729973, https://openalex.org/W4378348349, https://openalex.org/W2019565950, https://openalex.org/W4283390966, https://openalex.org/W2970380227 |
| referenced_works_count | 32 |
| abstract_inverted_index.( | 170, 188, 198, 222 |
| abstract_inverted_index.- | 91 |
| abstract_inverted_index.= | 172, 190, 200, 224 |
| abstract_inverted_index.a | 76, 296 |
| abstract_inverted_index.n | 171, 189, 199, 223 |
| abstract_inverted_index.16 | 100 |
| abstract_inverted_index.2% | 187 |
| abstract_inverted_index.24 | 65, 102, 106, 165, 194, 210, 230, 236, 266, 287, 298 |
| abstract_inverted_index.28 | 176 |
| abstract_inverted_index.3% | 276 |
| abstract_inverted_index.4% | 305 |
| abstract_inverted_index.As | 309 |
| abstract_inverted_index.In | 2, 272 |
| abstract_inverted_index.To | 41 |
| abstract_inverted_index.We | 70, 125 |
| abstract_inverted_index.as | 96 |
| abstract_inverted_index.at | 86, 160, 205 |
| abstract_inverted_index.by | 116, 129, 239, 246, 251, 304 |
| abstract_inverted_index.is | 34 |
| abstract_inverted_index.mg | 66, 107, 237, 267, 288, 299 |
| abstract_inverted_index.no | 255 |
| abstract_inverted_index.of | 54, 57, 79, 148, 174, 202, 215, 226, 233, 277, 286, 292, 306 |
| abstract_inverted_index.on | 343 |
| abstract_inverted_index.to | 4, 74, 101, 316, 324, 358 |
| abstract_inverted_index.(16 | 19 |
| abstract_inverted_index.(24 | 26 |
| abstract_inverted_index.(4% | 214 |
| abstract_inverted_index.26% | 197 |
| abstract_inverted_index.28% | 232 |
| abstract_inverted_index.80% | 291 |
| abstract_inverted_index.FDA | 283, 334 |
| abstract_inverted_index.age | 132 |
| abstract_inverted_index.and | 21, 52, 63, 104, 110, 114, 119, 122, 137, 140, 142, 145, 154, 248, 262, 311, 352 |
| abstract_inverted_index.are | 319 |
| abstract_inverted_index.but | 32 |
| abstract_inverted_index.for | 220, 295, 346 |
| abstract_inverted_index.may | 28, 336 |
| abstract_inverted_index.mg) | 20, 27 |
| abstract_inverted_index.mg, | 62, 103 |
| abstract_inverted_index.mg. | 166, 195, 231 |
| abstract_inverted_index.mg; | 186, 211 |
| abstract_inverted_index.one | 207 |
| abstract_inverted_index.pay | 313 |
| abstract_inverted_index.per | 268 |
| abstract_inverted_index.the | 13, 50, 161, 175, 282, 293, 331 |
| abstract_inverted_index.use | 81, 329 |
| abstract_inverted_index.was | 254 |
| abstract_inverted_index.≤ | 58, 97 |
| abstract_inverted_index.> | 60, 64, 99, 105, 164, 184, 193, 209, 229, 235, 265, 297 |
| abstract_inverted_index.2019 | 90 |
| abstract_inverted_index.6.7% | 249 |
| abstract_inverted_index.cash | 344 |
| abstract_inverted_index.data | 73 |
| abstract_inverted_index.dose | 18, 25, 151, 301 |
| abstract_inverted_index.from | 180 |
| abstract_inverted_index.rate | 261 |
| abstract_inverted_index.sex, | 131 |
| abstract_inverted_index.such | 338, 359 |
| abstract_inverted_index.than | 275 |
| abstract_inverted_index.this | 47 |
| abstract_inverted_index.use, | 8 |
| abstract_inverted_index.used | 71 |
| abstract_inverted_index.were | 183, 192, 218, 242, 302 |
| abstract_inverted_index.when | 361 |
| abstract_inverted_index.12.5% | 244 |
| abstract_inverted_index.16-24 | 61, 185 |
| abstract_inverted_index.16mg, | 59, 98 |
| abstract_inverted_index.19.5% | 169 |
| abstract_inverted_index.2,780 | 212 |
| abstract_inverted_index.2020; | 93 |
| abstract_inverted_index.82.2% | 221 |
| abstract_inverted_index.IQVIA | 72 |
| abstract_inverted_index.There | 253 |
| abstract_inverted_index.about | 36 |
| abstract_inverted_index.among | 155 |
| abstract_inverted_index.could | 355 |
| abstract_inverted_index.daily | 10, 17, 24, 67, 108, 150, 289, 300, 348 |
| abstract_inverted_index.dose. | 68 |
| abstract_inverted_index.dose; | 109, 290 |
| abstract_inverted_index.doses | 11, 349 |
| abstract_inverted_index.fewer | 274 |
| abstract_inverted_index.known | 35 |
| abstract_inverted_index.least | 206 |
| abstract_inverted_index.rates | 113, 115 |
| abstract_inverted_index.state | 141, 258 |
| abstract_inverted_index.study | 78 |
| abstract_inverted_index.their | 327 |
| abstract_inverted_index.these | 240 |
| abstract_inverted_index.treat | 326 |
| abstract_inverted_index.wrote | 204 |
| abstract_inverted_index.68,898 | 181 |
| abstract_inverted_index.access | 357 |
| abstract_inverted_index.better | 30, 42 |
| abstract_inverted_index.county | 120 |
| abstract_inverted_index.dosage | 38 |
| abstract_inverted_index.doses, | 163 |
| abstract_inverted_index.higher | 37, 347 |
| abstract_inverted_index.little | 33 |
| abstract_inverted_index.opioid | 80, 328 |
| abstract_inverted_index.public | 351 |
| abstract_inverted_index.retail | 87 |
| abstract_inverted_index.target | 16 |
| abstract_inverted_index.17,939) | 201 |
| abstract_inverted_index.FDA’s | 14 |
| abstract_inverted_index.January | 89 |
| abstract_inverted_index.Methods | 69 |
| abstract_inverted_index.Results | 167 |
| abstract_inverted_index.between | 257 |
| abstract_inverted_index.cohort, | 133 |
| abstract_inverted_index.conduct | 75 |
| abstract_inverted_index.covered | 245, 250 |
| abstract_inverted_index.dosages | 322 |
| abstract_inverted_index.greater | 5, 314 |
| abstract_inverted_index.highest | 162 |
| abstract_inverted_index.illicit | 6 |
| abstract_inverted_index.insurer | 118 |
| abstract_inverted_index.maximum | 22, 285 |
| abstract_inverted_index.million | 177 |
| abstract_inverted_index.overall | 112, 153 |
| abstract_inverted_index.patient | 130 |
| abstract_inverted_index.payment | 135, 345 |
| abstract_inverted_index.primary | 134 |
| abstract_inverted_index.private | 353 |
| abstract_inverted_index.provide | 29 |
| abstract_inverted_index.revised | 333 |
| abstract_inverted_index.source, | 136 |
| abstract_inverted_index.written | 238, 303 |
| abstract_inverted_index.527,597) | 225 |
| abstract_inverted_index.641,390) | 191 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.December | 92 |
| abstract_inverted_index.adequate | 323 |
| abstract_inverted_index.analyses | 147 |
| abstract_inverted_index.ensuring | 317 |
| abstract_inverted_index.examined | 111 |
| abstract_inverted_index.examines | 49 |
| abstract_inverted_index.exceeded | 281 |
| abstract_inverted_index.fentanyl | 7, 259 |
| abstract_inverted_index.insurers | 354 |
| abstract_inverted_index.overdose | 260 |
| abstract_inverted_index.patient, | 117 |
| abstract_inverted_index.recently | 332 |
| abstract_inverted_index.reliance | 342 |
| abstract_inverted_index.response | 3 |
| abstract_inverted_index.suggests | 350 |
| abstract_inverted_index.1,000,000 | 269 |
| abstract_inverted_index.Medicaid, | 247 |
| abstract_inverted_index.Medicare. | 252 |
| abstract_inverted_index.attention | 315 |
| abstract_inverted_index.behavior. | 339 |
| abstract_inverted_index.bivariate | 146 |
| abstract_inverted_index.cash-pay, | 243 |
| abstract_inverted_index.conducted | 143 |
| abstract_inverted_index.disorder, | 330 |
| abstract_inverted_index.dispensed | 55, 85, 227, 278 |
| abstract_inverted_index.encourage | 337 |
| abstract_inverted_index.exceeding | 12 |
| abstract_inverted_index.frequency | 51 |
| abstract_inverted_index.outcomes, | 31 |
| abstract_inverted_index.patterns, | 46 |
| abstract_inverted_index.patterns. | 40 |
| abstract_inverted_index.receiving | 320 |
| abstract_inverted_index.specialty | 139 |
| abstract_inverted_index.suggested | 23, 284 |
| abstract_inverted_index.treatment | 360 |
| abstract_inverted_index.5,568,964) | 173 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.categories | 152 |
| abstract_inverted_index.clinicians | 156, 182, 203, 213, 310 |
| abstract_inverted_index.facilitate | 356 |
| abstract_inverted_index.frequently | 157 |
| abstract_inverted_index.manuscript | 48 |
| abstract_inverted_index.pharmacies | 88 |
| abstract_inverted_index.prescriber | 123, 138 |
| abstract_inverted_index.residents. | 270 |
| abstract_inverted_index.specialty. | 124 |
| abstract_inverted_index.understand | 43 |
| abstract_inverted_index.univariate | 144 |
| abstract_inverted_index.Conclusions | 271 |
| abstract_inverted_index.categorized | 94, 126 |
| abstract_inverted_index.correlation | 256 |
| abstract_inverted_index.effectively | 325 |
| abstract_inverted_index.individuals | 318 |
| abstract_inverted_index.prescribers | 241 |
| abstract_inverted_index.prescribing | 39, 45, 158 |
| abstract_inverted_index.recommended | 15 |
| abstract_inverted_index.responsible | 219 |
| abstract_inverted_index.2019–2020, | 273 |
| abstract_inverted_index.appropriate. | 362 |
| abstract_inverted_index.policymakers | 312 |
| abstract_inverted_index.prescribers) | 217 |
| abstract_inverted_index.prescribers. | 308 |
| abstract_inverted_index.prescription | 208 |
| abstract_inverted_index.Additionally, | 340 |
| abstract_inverted_index.Approximately | 168, 196 |
| abstract_inverted_index.buprenorphine | 9, 44, 56, 83, 127, 149, 159, 178, 216, 263, 279, 307, 321 |
| abstract_inverted_index.prescriptions | 84, 95, 128, 179, 228, 234, 264, 280, 294 |
| abstract_inverted_index.characteristics | 53 |
| abstract_inverted_index.cross-sectional | 77 |
| abstract_inverted_index.recommendations | 335 |
| abstract_inverted_index.characteristics, | 121 |
| abstract_inverted_index.disproportionate | 341 |
| abstract_inverted_index.disorder-indicated | 82 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| citation_normalized_percentile.value | 0.87958396 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |